Phoenix Biotechnology, Inc. (PBI)'s Focus
Phoenix Biotechnology, Inc., has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.
PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.
A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.
“Antiviral effects of oleandrin". Letter to the editor of the Journal of the American College of Emergency Physicians. Newman, R. and Jagannadha Sastry, K. (2021). JACEP Open, 2: e12469.
Our recent research with oleandrin as a proposed inhibitor of SARS-CoV-2 has demonstrated that low nanomolar concentrations of this molecule achieved near-total inhibition of the relative infectivity of this virus. The effective antiviral oleandrin concentrations were a fraction of that required for the control of cancer cell lines. This suggests that the use of oleandrin or a properly defined extract containing this molecule could be used to control COVID-19 without toxicity.
“Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2". Biomedicine & Pharmacotherapy.
With continued expansion of COVID-19 caused by the severe respiratory syndrome 2 (SARS-CoV-2) antiviral therapies as well as effective vaccines are desperately needed. This article presents evidence for the significant inhibition of SARS-CoV-2 by oleandrin and the company's experimental product PBI-06150.